InvestorsHub Logo
Followers 95
Posts 9573
Boards Moderated 2
Alias Born 03/25/2013

Re: Quintessence post# 157

Monday, 06/10/2019 8:56:17 AM

Monday, June 10, 2019 8:56:17 AM

Post# of 632
"Avalon will hold a press conference to announce the launch of its exosome product commercialization plan, including a series of over-the-counter skincare and wound-healing products with Avalon's Clinical-grade Tissue-specific EXosomes as additives (ACTEX), on June 15, 2019 during the 2nd International Aesthetic Industry Conference in Chengdu, China -- the largest conference of its kind in Asia. In addition to product commercialization, this standardization of clinical-grade stem cell derived exosomes will lead to parallel development of Avalon's clinical programs, including AVA-202 and AVA-203, for angiogenic/orthopedic regeneration as well as treatment of fibrotic diseases."

https://finance.yahoo.com/news/avalon-globocare-announces-completion-clinical-120000239.html

JMHO. DYODD. "An investment in knowledge pays the best interest." - Benjamin Franklin

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALBT News